Lipitor, Atorvastatin Calcium Hydrate Greatly Inhibits Coronary Artery Plaque Progression: Yamanouchi Pharmaceutical Co., Ltd., Pfizer Japan 
10/19/2005 5:12:35 PM

Tokyo (JCNN) - Yamanouchi Pharmaceutical (TSE: 4503) and Pfizer Japan jointly announced that the positive results of REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) trials on Lipitor, an atorvastatin calcium hydrate, were published in the January 6 issue of the New England Journal of Medicine (NEJM).